Date: September 30, 2026
Regulatory Compliance Disclosure
This document serves as a clarification to the previous disclosure dated 28 September 2026 (Reference: ARILSLDSTX20260928066) regarding the acquisition of equity shares in Bliss GVS Pharma Limited ("Bliss"). The company identifies and corrects certain inadvertent typographical errors in the previous disclosure.
Acquisition Details Clarification
Transaction Completion
- The Acquirer (Anupam Rasayan India Limited) along with PAC (Mates Visa Consultancy Private Limited) consummated the transactions under the Share Purchase Agreement (SPA) on 28 September 2026
- This transaction is referred to as the "Underlying Transaction"
- The PAC acquired 5,09,84,595 equity shares of Bliss representing 47.95% of the company
Correction of Typographical Error
- The previous disclosure incorrectly stated "1,699 equity shares" of Bliss were credited to the demat account of the Acquirer on 24 August 2026
- The correct number is "1,669 equity shares"
Summary of Total Acquisitions
- Acquirer (Anupam Rasayan India Limited): 22,51,669 equity shares (comprising 22,50,000 shares + 1,669 shares)
- PAC (Mates Visa Consultancy Private Limited): 5,09,84,595 equity shares
Legal Framework
- The acquisition was executed under the Share Purchase Agreement dated 23 May 2026 among Anupam Rasayan India Limited and multiple sellers including Narsimha Shibroor Kamath, Vibha Gagan Sharma, Shruti Vishal Rao, Gautam Rasiklal Ashra, Arjun Gautam Ashra and Gulbarga Trading and Investment Private Limited
- The Deed of Adherence dated 17 July 2026 was executed between the Acquirer and Mates Visa Consultancy Private Limited (the "PAC") pursuant to the open offer
- Disclosure made under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
Additional Information
- All other contents of the previous disclosure remain unchanged
- This intimation will be hosted on the company website at www.anupamrasayan.com